A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs GRF 6021 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Alkahest
- 26 Mar 2019 According to an Alkahest media release, data from the study will be presented at the 14th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2019.
- 04 Dec 2018 According to a Alkahest media release, first patient has been dosed in this trial. This trial is being conducted with support from The Michael J. Fox Foundation.
- 20 Nov 2018 Status changed from not yet recruiting to recruiting.